0001209191-22-014652.txt : 20220302
0001209191-22-014652.hdr.sgml : 20220302
20220302160108
ACCESSION NUMBER: 0001209191-22-014652
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220228
FILED AS OF DATE: 20220302
DATE AS OF CHANGE: 20220302
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shetzline Michael
CENTRAL INDEX KEY: 0001808509
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34620
FILM NUMBER: 22703294
MAIL ADDRESS:
STREET 1: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IRONWOOD PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001446847
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043404176
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 617-621-7722
MAIL ADDRESS:
STREET 1: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-02-28
0
0001446847
IRONWOOD PHARMACEUTICALS INC
IRWD
0001808509
Shetzline Michael
C/O IRONWOOD PHARMACEUTICALS, INC.
100 SUMMER STREET, SUITE 2300
BOSTON
MA
02110
0
1
0
0
CMO,SVP,Head-Res&Drug
Class A Common Stock
2022-02-28
4
S
0
1367
10.77
D
211620
D
Class A Common Stock
2022-02-28
4
S
0
2911
10.77
D
208709
D
Class A Common Stock
2022-02-28
4
S
0
5161
10.77
D
203548
D
Class A Common Stock
2022-02-28
4
S
0
3804
10.77
D
199744
D
Class A Common Stock
2022-02-28
4
S
0
4364
10.77
D
195380
D
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2019.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting of the reporting person's performance-based restricted stock units granted on February 27, 2020.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting of the reporting person's performance-based restricted stock units granted on April 24, 2020
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February 22, 2021.
/s/ Brian Tessler, Attorney-in-Fact
2022-03-02